Stryker Co. (NYSE:SYK) Shares Purchased by NewEdge Advisors LLC

NewEdge Advisors LLC grew its stake in shares of Stryker Co. (NYSE:SYK) by 16.4% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 27,487 shares of the medical technology company’s stock after acquiring an additional 3,873 shares during the period. NewEdge Advisors LLC’s holdings in Stryker were worth $9,897,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the stock. Kohmann Bosshard Financial Services LLC acquired a new position in shares of Stryker in the 4th quarter valued at $25,000. Rakuten Securities Inc. boosted its holdings in shares of Stryker by 618.2% in the fourth quarter. Rakuten Securities Inc. now owns 79 shares of the medical technology company’s stock worth $28,000 after buying an additional 68 shares during the period. Centricity Wealth Management LLC purchased a new position in shares of Stryker in the fourth quarter worth approximately $30,000. BankPlus Trust Department acquired a new stake in shares of Stryker during the fourth quarter valued at approximately $33,000. Finally, Activest Wealth Management acquired a new position in Stryker in the 4th quarter worth approximately $36,000. 77.09% of the stock is owned by institutional investors.

Insider Buying and Selling at Stryker

In other news, Director Allan C. Golston sold 2,458 shares of the firm’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total transaction of $941,586.06. Following the completion of the transaction, the director now directly owns 14,895 shares of the company’s stock, valued at approximately $5,705,827.65. This trade represents a 14.16 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Ronda E. Stryker sold 201,392 shares of the company’s stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the completion of the sale, the director now directly owns 3,642,075 shares in the company, valued at approximately $1,428,567,498. The trade was a 5.24 % decrease in their position. The disclosure for this sale can be found here. Insiders own 5.90% of the company’s stock.

Stryker Stock Down 0.1 %

Stryker stock opened at $346.46 on Friday. Stryker Co. has a fifty-two week low of $314.93 and a fifty-two week high of $406.19. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32. The firm has a market cap of $132.24 billion, a price-to-earnings ratio of 44.65, a P/E/G ratio of 2.93 and a beta of 0.93. The firm has a fifty day moving average price of $371.83 and a two-hundred day moving average price of $373.11.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, topping analysts’ consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same quarter last year, the firm earned $3.46 earnings per share. As a group, analysts forecast that Stryker Co. will post 13.47 earnings per share for the current year.

Stryker Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be paid a $0.84 dividend. This represents a $3.36 annualized dividend and a dividend yield of 0.97%. The ex-dividend date is Monday, March 31st. Stryker’s payout ratio is presently 43.30%.

Analyst Upgrades and Downgrades

SYK has been the topic of several recent analyst reports. JPMorgan Chase & Co. boosted their target price on shares of Stryker from $420.00 to $445.00 and gave the company an “overweight” rating in a research note on Wednesday, January 29th. The Goldman Sachs Group set a $422.00 target price on Stryker in a report on Tuesday, March 4th. Truist Financial upped their price objective on shares of Stryker from $409.00 to $413.00 and gave the company a “hold” rating in a research note on Thursday, January 30th. Barclays upped their price target on shares of Stryker from $418.00 to $443.00 and gave the stock an “overweight” rating in a research note on Monday, February 10th. Finally, Canaccord Genuity Group upped their target price on Stryker from $420.00 to $435.00 and gave the stock a “buy” rating in a research report on Wednesday, January 29th. Five investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. Based on data from MarketBeat, Stryker has an average rating of “Moderate Buy” and a consensus target price of $423.53.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.